Literature DB >> 23115287

Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus.

Donald M Carter1, Chalise E Bloom, Eduardo J M Nascimento, Ernesto T A Marques, Jodi K Craigo, Joshua L Cherry, David J Lipman, Ted M Ross.   

Abstract

Individuals <60 years of age had the lowest incidence of infection, with ~25% of these people having preexisting, cross-reactive antibodies to novel 2009 H1N1 influenza. Many people >60 years old also had preexisting antibodies to novel H1N1. These observations are puzzling because the seasonal H1N1 viruses circulating during the last 60 years were not antigenically similar to novel H1N1. We therefore hypothesized that a sequence of exposures to antigenically different seasonal H1N1 viruses can elicit an antibody response that protects against novel 2009 H1N1. Ferrets were preinfected with seasonal H1N1 viruses and assessed for cross-reactive antibodies to novel H1N1. Serum from infected ferrets was assayed for cross-reactivity to both seasonal and novel 2009 H1N1 strains. These results were compared to those of ferrets that were sequentially infected with H1N1 viruses isolated prior to 1957 or more-recently isolated viruses. Following seroconversion, ferrets were challenged with novel H1N1 influenza virus and assessed for viral titers in the nasal wash, morbidity, and mortality. There was no hemagglutination inhibition (HAI) cross-reactivity in ferrets infected with any single seasonal H1N1 influenza viruses, with limited protection to challenge. However, sequential H1N1 influenza infections reduced the incidence of disease and elicited cross-reactive antibodies to novel H1N1 isolates. The amount and duration of virus shedding and the frequency of transmission following novel H1N1 challenge were reduced. Exposure to multiple seasonal H1N1 influenza viruses, and not to any single H1N1 influenza virus, elicits a breadth of antibodies that neutralize novel H1N1 even though the host was never exposed to the novel H1N1 influenza viruses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23115287      PMCID: PMC3554183          DOI: 10.1128/JVI.02257-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.

Authors:  T M Ross; Y Xu; R A Bright; H L Robinson
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

2.  Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October - December 2009.

Authors:  J McVernon; K Laurie; T Nolan; R Owen; D Irving; H Capper; C Hyland; H Faddy; L Carolan; I Barr; A Kelso
Journal:  Euro Surveill       Date:  2010-10-07

3.  Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Authors:  Rui Xu; Damian C Ekiert; Jens C Krause; Rong Hai; James E Crowe; Ian A Wilson
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

4.  The influenza virus resource at the National Center for Biotechnology Information.

Authors:  Yiming Bao; Pavel Bolotov; Dmitry Dernovoy; Boris Kiryutin; Leonid Zaslavsky; Tatiana Tatusova; Jim Ostell; David Lipman
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

5.  Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model.

Authors:  Taronna R Maines; Li-Mei Chen; Yumiko Matsuoka; Hualan Chen; Thomas Rowe; Juan Ortin; Ana Falcón; Tran Hien Nguyen; Le Quynh Mai; Endang R Sedyaningsih; Syahrial Harun; Terrence M Tumpey; Ruben O Donis; Nancy J Cox; Kanta Subbarao; Jacqueline M Katz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

6.  Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

Authors:  T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

7.  Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Authors:  Rick A Bright; Donald M Carter; Shannon Daniluk; Franklin R Toapanta; Attiya Ahmad; Victor Gavrilov; Mike Massare; Peter Pushko; Nutan Mytle; Thomas Rowe; Gale Smith; Ted M Ross
Journal:  Vaccine       Date:  2007-02-15       Impact factor: 3.641

8.  Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines.

Authors:  Balaji Manicassamy; Rafael A Medina; Rong Hai; Tshidi Tsibane; Silke Stertz; Estanislao Nistal-Villán; Peter Palese; Christopher F Basler; Adolfo García-Sastre
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

9.  Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins.

Authors:  Judy A Mitchell; Thomas D Green; Rick A Bright; Ted M Ross
Journal:  Vaccine       Date:  2003-02-14       Impact factor: 3.641

10.  An IgG avidity ELISA to discriminate between recent and chronic Neospora caninum infection.

Authors:  C Björkman; K Näslund; S Stenlund; S W Maley; D Buxton; A Uggla
Journal:  J Vet Diagn Invest       Date:  1999-01       Impact factor: 1.279

View more
  33 in total

1.  Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Authors:  Donald M Carter; Christopher A Darby; Bradford C Lefoley; Corey J Crevar; Timothy Alefantis; Raymond Oomen; Stephen F Anderson; Tod Strugnell; Guadalupe Cortés-Garcia; Thorsten U Vogel; Mark Parrington; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  Contact between bird species of different lifespans can promote the emergence of highly pathogenic avian influenza strains.

Authors:  Paul S Wikramaratna; Oliver G Pybus; Sunetra Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

3.  Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season.

Authors:  Susanne L Linderman; Benjamin S Chambers; Seth J Zost; Kaela Parkhouse; Yang Li; Christin Herrmann; Ali H Ellebedy; Donald M Carter; Sarah F Andrews; Nai-Ying Zheng; Min Huang; Yunping Huang; Donna Strauss; Beth H Shaz; Richard L Hodinka; Gustavo Reyes-Terán; Ted M Ross; Patrick C Wilson; Rafi Ahmed; Jesse D Bloom; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-20       Impact factor: 11.205

4.  Influenza vaccination and the 'diversity paradox'.

Authors:  Craig P Thompson; Uri Obolski
Journal:  Hum Vaccin Immunother       Date:  2018-09-21       Impact factor: 3.452

5.  High preexisting serological antibody levels correlate with diversification of the influenza vaccine response.

Authors:  Sarah F Andrews; Kaval Kaur; Noel T Pauli; Min Huang; Yunping Huang; Patrick C Wilson
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

Review 6.  Complexities in Ferret Influenza Virus Pathogenesis and Transmission Models.

Authors:  Jessica A Belser; Alissa M Eckert; Terrence M Tumpey; Taronna R Maines
Journal:  Microbiol Mol Biol Rev       Date:  2016-07-13       Impact factor: 11.056

7.  Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.

Authors:  James D Allen; Hyesun Jang; Joshua DiNapoli; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

8.  Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies.

Authors:  Claudia P Arevalo; Valerie Le Sage; Marcus J Bolton; Theresa Eilola; Jennifer E Jones; Karen A Kormuth; Eric Nturibi; Angel Balmaseda; Aubree Gordon; Seema S Lakdawala; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-06       Impact factor: 11.205

9.  Increased frequency of travel in the presence of cross-immunity may act to decrease the chance of a global pandemic.

Authors:  R N Thompson; C P Thompson; O Pelerman; S Gupta; U Obolski
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-06-24       Impact factor: 6.237

Review 10.  Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories.

Authors:  Scott E Hensley
Journal:  Curr Opin Virol       Date:  2014-08-11       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.